Objectives To investigate the effects of dapagliflozin on renal function in patients with coronary heart disease (CHD) complicated with diabetes mellitus type 2 (T2DM) and mild-to-moderate renal insufficiency following percutaneous coronary intervention (PCI). Methods A total of 60 patients with CHD complicated with T2DM and mild-to-moderate renal insufficiency who underwent PCI were randomly divided into an intervention group and a control group, with 30 cases in each group. The control group received conventional treatment, whereas the intervention group received oral dapagliflozin in addition to conventional treatment. The following parameters were compared between the two groups: serum creatinine, blood urea nitrogen (BUN), creatinine clearance rate (CCR), estimated glomerular filtration rate (eGFR), and serum superoxide dismu-tase (SOD), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) levels. The occurrence of contrast induced nephropathy (CIN) during the treatment period was also observed. Results At 72 hours postoperatively, both groups exhibited elevated serum creatinine and BUN levels compared with preoperative levels, with the intervention group demonstrating significantly lower levels than the control group (P<0.05). Both groups showed decreased CCR and eGFR compared with preoperative levels, with the intervention group exhibiting significantly higher levels than the control group (P<0.05). At 72 hours postoperatively, both groups demonstrated elevated levels of serum SOD, MDA, IL-6, and TNF-α compared with preoperative levels, with the intervention group showing significantly lower levels of these biomarkers than the control group (P<0.05). Conclusion Dapagliflozin exerts an improving effect on renal function in patients with CHD complicated with T2DM and mild-to-moderate renal insufficiency following PCI. This improving effect may exert its action through reducing levels of inflammatory cytokines and alleviating oxidative stress.

无